<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39019922</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>17</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy.</ArticleTitle><Pagination><StartPage>16524</StartPage><MedlinePgn>16524</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">16524</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-66817-0</ELocationID><Abstract><AbstractText>Recent clinical trials have found that the serotonergic psychedelic psilocybin effectively alleviates anxiodepressive symptoms in patients with life-threatening illnesses when given in a supportive environment. These outcomes prompted Canada to establish legal pathways for therapeutic access to psilocybin, coupled with psychological support. Despite over one-hundred Canadians receiving compassionate access since 2020, there has been little examination of these 'real-world' patients. We conducted a prospective longitudinal survey which focused on Canadians who were granted Section&#xa0;56 exemptions for legal psilocybin-assisted psychotherapy. Surveys assessing various symptom dimensions were conducted at baseline, two weeks following the session (endpoint), and optionally one day post-session. Participant characteristics were examined using descriptive statistics, and paired sample t-tests were used to quantify changes from baseline to the two-week post-treatment endpoint. Eight participants with Section&#xa0;56 exemptions (four females, M<sub>age</sub>&#x2009;=&#x2009;52.3&#xa0;years), all with cancer diagnoses, fully completed baseline and endpoint surveys. Significant improvements in anxiety and depression symptoms, pain, fear of COVID-19, quality of life, and spiritual well-being were observed. Attitudes towards death, medical assistance in dying, and desire for hastened death remained unchanged. While most participants found the psilocybin sessions highly meaningful, if challenging, one reported a substantial decrease in well-being due to the experience. These preliminary data are amongst the first to suggest that psilocybin-assisted psychotherapy can produce psychiatric benefits in real-world patients akin to those observed in clinical trials. Limited enrollment and individual reports of negative experiences indicate the need for formal real-world evaluation programs to surveil the ongoing expansion of legal access to psychedelics.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>de la Salle</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, McGill University, Montr&#xe9;al, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lady Davis Institute at the Jewish General Hospital, Montr&#xe9;al, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kettner</LastName><ForeName>Hannes</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Centre for Psychedelic Research, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thibault L&#xe9;vesque</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Lady Davis Institute at the Jewish General Hospital, Montr&#xe9;al, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garel</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Addictology, Faculty of Medicine, Universit&#xe9; de Montr&#xe9;al, 2900 Boul. Edouard-Montpetit, Montr&#xe9;al, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Centre, Centre Hospitaller de L'Universit&#xe9; de Montr&#xe9;al (CRCHUM), 900 Saint-Denis Street, Montr&#xe9;al, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dames</LastName><ForeName>Shannon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Health and Human Services, Vancouver Island University, Nanaimo, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patchett-Marble</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Northern Ontario School of Medicine University, Thunder Bay, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Marathon Family Health Team, Marathon, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rej</LastName><ForeName>Soham</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, McGill University, Montr&#xe9;al, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lady Davis Institute at the Jewish General Hospital, Montr&#xe9;al, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Nursing and Midwifery, Queen's University Belfast, Belfast, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gloeckler</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, McGill University, Montr&#xe9;al, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lady Davis Institute at the Jewish General Hospital, Montr&#xe9;al, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erritzoe</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Psychedelic Research, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carhart-Harris</LastName><ForeName>Robin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Psychedelic Research, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenway</LastName><ForeName>Kyle T</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, McGill University, Montr&#xe9;al, Canada. Kyle.greenway@mcgill.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Psychedelic Research, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK. Kyle.greenway@mcgill.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lady Davis Institute at the Jewish General Hospital, Montr&#xe9;al, Canada. Kyle.greenway@mcgill.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006213">Hallucinogens</NameOfSubstance></Chemical><Chemical><RegistryNumber>2RV7212BP0</RegistryNumber><NameOfSubstance UI="D011562">Psilocybin</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Population" UI="C000726214">Canadian people</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057176" MajorTopicYN="N">Compassionate Use Trials</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006213" MajorTopicYN="Y">Hallucinogens</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094858" MajorTopicYN="N">North American People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011562" MajorTopicYN="Y">Psilocybin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="Y">Psychotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Distress</Keyword><Keyword MajorTopicYN="N">Palliative care</Keyword><Keyword MajorTopicYN="N">Psilocybin-assisted psychotherapy</Keyword><Keyword MajorTopicYN="N">Psychedelics</Keyword></KeywordList><CoiStatement>R.C.-H. is a scientific advisor to Otsuka, Entheos, Osmind, Joruney Collab and Mindstate. D.E. is a scientific advisor for Aya Biosciences, Lophora Aps, Clerkenwell Health, and Mindstate Design Lab. None of the aforementioned organizations were involved in the design, execution, interpretation, or communication of findings from present study. The rest of the authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>18</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>18</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>17</Day><Hour>23</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39019922</ArticleId><ArticleId IdType="pmc">PMC11254907</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-66817-0</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-66817-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hofmann A, Heim R, Brack A, Kobel H. Psilocybin, a psychotropic substance from the Mexican mushroom Psilicybe mexicana Heim. Experientia. 1958;14:107&#x2013;109. doi: 10.1007/BF02159243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02159243</ArticleId><ArticleId IdType="pubmed">13537892</ArticleId></ArticleIdList></Reference><Reference><Citation>Legislative Services Branch. Consolidated federal laws of Canada, Controlled Drugs and Substances Act. https://laws-lois.justice.gc.ca/eng/acts/C-38.8/section-sched95602.html?txthl=psilocybin (2023).</Citation></Reference><Reference><Citation>Davis AK, et al. Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiat. 2021;78:481. doi: 10.1001/jamapsychiatry.2020.3285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2020.3285</ArticleId><ArticleId IdType="pmc">PMC7643046</ArticleId><ArticleId IdType="pubmed">33146667</ArticleId></ArticleIdList></Reference><Reference><Citation>von Rotz R, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine. 2023;28:56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9830149</ArticleId><ArticleId IdType="pubmed">36636296</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber GS, Aaronson ST. The emerging field of psychedelic psychotherapy. Curr. Psychiatry Rep. 2022;24:583&#x2013;590. doi: 10.1007/s11920-022-01363-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11920-022-01363-y</ArticleId><ArticleId IdType="pmc">PMC9553847</ArticleId><ArticleId IdType="pubmed">36129571</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths RR, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J. Psychopharmacol. 2016;30:1181&#x2013;1197. doi: 10.1177/0269881116675513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269881116675513</ArticleId><ArticleId IdType="pmc">PMC5367557</ArticleId><ArticleId IdType="pubmed">27909165</ArticleId></ArticleIdList></Reference><Reference><Citation>Grob CS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch. Gen. Psychiatry. 2011;68:71&#x2013;78. doi: 10.1001/archgenpsychiatry.2010.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archgenpsychiatry.2010.116</ArticleId><ArticleId IdType="pubmed">20819978</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross S, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J. Psychopharmacol. 2016;30:1165&#x2013;1180. doi: 10.1177/0269881116675512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269881116675512</ArticleId><ArticleId IdType="pmc">PMC5367551</ArticleId><ArticleId IdType="pubmed">27909164</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross S, et al. Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care. Neuropharmacology. 2022;216:109174. doi: 10.1016/j.neuropharm.2022.109174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2022.109174</ArticleId><ArticleId IdType="pubmed">35772523</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayner L, et al. Antidepressants for the treatment of depression in palliative care: Systematic review and meta-analysis. Palliat. Med. 2011;25:36&#x2013;51. doi: 10.1177/0269216310380764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269216310380764</ArticleId><ArticleId IdType="pubmed">20935027</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauerei&#xdf; N, Obermaier S, &#xd6;z&#xfc;nal SE, Baumeister H. Effects of existential interventions on spiritual, psychological, and physical well-being in adult patients with cancer: Systematic review and meta-analysis of randomized controlled trials. Psychooncology. 2018;27:2531&#x2013;2545. doi: 10.1002/pon.4829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.4829</ArticleId><ArticleId IdType="pubmed">29958339</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, et al. Effectiveness of dignity therapy for patients with advanced cancer: A systematic review and meta-analysis of 10 randomized controlled trials. Depress Anxiety. 2020;37:234&#x2013;246. doi: 10.1002/da.22980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/da.22980</ArticleId><ArticleId IdType="pubmed">31808977</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas AS, Lu&#xed;s &#xc2;, Barroso M, Gallardo E, Pereira L. Psilocybin as a new approach to treat depression and anxiety in the context of life-threatening diseases&#x2014;A systematic review and meta-analysis of clinical trials. Biomedicines. 2020;8:331. doi: 10.3390/biomedicines8090331.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines8090331</ArticleId><ArticleId IdType="pmc">PMC7554922</ArticleId><ArticleId IdType="pubmed">32899469</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C-L, et al. Psilocybin for end-of-life anxiety symptoms: a systematic review and meta-analysis. Psychiatry Investig. 2021;18:958&#x2013;967. doi: 10.30773/pi.2021.0209.</Citation><ArticleIdList><ArticleId IdType="doi">10.30773/pi.2021.0209</ArticleId><ArticleId IdType="pmc">PMC8542741</ArticleId><ArticleId IdType="pubmed">34619818</ArticleId></ArticleIdList></Reference><Reference><Citation>Argento E, Christie D, Mackay L, Callon C, Walsh Z. Psychedelic-assisted psychotherapy after COVID-19: The therapeutic uses of psilocybin and MDMA for pandemic-related mental health problems. Front. Psychiatry. 2021 doi: 10.3389/fpsyt.2021.716593.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2021.716593</ArticleId><ArticleId IdType="pmc">PMC8450400</ArticleId><ArticleId IdType="pubmed">34552518</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon Ritchie O, Donley CN, Dixon Ritchie G. From prohibited to prescribed: The rescheduling of MDMA and psilocybin in Australia. Drug Sci. Policy Law. 2023;9:20503245231198472. doi: 10.1177/20503245231198472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20503245231198472</ArticleId></ArticleIdList></Reference><Reference><Citation>Oregon Health Authority&#x202f;: Oregon Psilocybin Services&#x202f;: Prevention and Wellness&#x202f;: State of Oregon. https://www.oregon.gov/oha/ph/preventionwellness/pages/oregon-psilocybin-services.aspx.</Citation></Reference><Reference><Citation>Canada, H. Psilocybin and psilocin (Magic mushrooms). https://www.canada.ca/en/health-canada/services/substance-use/controlled-illegal-drugs/magic-mushrooms.html (2012).</Citation></Reference><Reference><Citation>TheraPSil. Palliative Canadians approved for end of life psilocybin therapy through section 56(1)&#x202f;; First legal medical exemptions for psilocybin in Canada since 1970&#x2019;s. TheraPsilhttps://therapsil.ca/4-palliative-canadians-approved-for-end-of-life-psilocybin-therapy-through-section-561-first-legal-medical-exemptions-for-psilocybin-in-canada-since-1970s/ (2020).</Citation></Reference><Reference><Citation>TheraPSil. 17 Canadian Healthcare Professionals Approved to Use Psilocybin for Professional Training. TheraPsilhttps://therapsil.ca/17-canadian-healthcare-professionals-approved-to-use-psilocybin-for-professional-training/ (2020).</Citation></Reference><Reference><Citation>Notice to stakeholders: Requests to the Special Access Program (SAP) involving psychedelic-assisted psychotherapy. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html (2023).</Citation></Reference><Reference><Citation>House of Commons. Compassionate Access to Investigational Therapies. Second Report of the Standing Committee on Healthhttps://www.ourcommons.ca/Archives/committee/352/sant/reports/02_1996-10/sant-02-report-e.html.</Citation></Reference><Reference><Citation>TheraPSil. Quebec first province to cover costs of psilocybin-assisted psychotherapy, done by two physicians. TheraPsilhttps://therapsil.ca/quebec-first-province-to-cover-costs-of-psilocybin-assisted-psychotherapy-done-by-two-physicians/ (2022).</Citation></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. J. Gen. Intern. Med. 2001;16:606&#x2013;613. doi: 10.1046/j.1525-1497.2001.016009606.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1525-1497.2001.016009606.x</ArticleId><ArticleId IdType="pmc">PMC1495268</ArticleId><ArticleId IdType="pubmed">11556941</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer RL, Kroenke K, Williams JBW, L&#xf6;we B. A brief measure for assessing generalized anxiety disorder: The GAD-7. Arch. Intern. Med. 2006;166:1092&#x2013;1097. doi: 10.1001/archinte.166.10.1092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.166.10.1092</ArticleId><ArticleId IdType="pubmed">16717171</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen SR, et al. Measuring the quality of life of people at the end of life: The McGill quality of life questionnaire-revised. Palliat. Med. 2017;31:120&#x2013;129. doi: 10.1177/0269216316659603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269216316659603</ArticleId><ArticleId IdType="pubmed">27412257</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterman AH, Fitchett G, Brady MJ, Hernandez L, Cella D. Measuring spiritual well-being in people with cancer: The functional assessment of chronic illness therapy&#x2013;spiritual well-being scale (FACIT-Sp) Ann. Behav. Med. 2002;24:49&#x2013;58. doi: 10.1207/S15324796ABM2401_06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1207/S15324796ABM2401_06</ArticleId><ArticleId IdType="pubmed">12008794</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy PE, et al. An examination of the 3-factor model and structural invariance across racial/ethnic groups for the FACIT-Sp: A report from the American Cancer Society&#x2019;s Study of Cancer Survivors-II (SCS-II) Psychooncology. 2010;19:264&#x2013;272. doi: 10.1002/pon.1559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.1559</ArticleId><ArticleId IdType="pubmed">19367561</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe SM, et al. A multicenter study comparing two numerical versions of the edmonton symptom assessment system in palliative care patients. J. Pain Symptom Manag. 2011;41:456&#x2013;468. doi: 10.1016/j.jpainsymman.2010.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpainsymman.2010.04.020</ArticleId><ArticleId IdType="pubmed">20832987</ArticleId></ArticleIdList></Reference><Reference><Citation>Canada, H. Medical assistance in dying: Overview. https://www.canada.ca/en/health-canada/services/health-services-benefits/medical-assistance-dying.html (2016).</Citation></Reference><Reference><Citation>Wong P, Reker G, Gesser G. Death attitude profile-revised: a multidimensional measure of attitude toward death. In: Neimeyer RA, editor. Death Anxiety Handbook. Taylor and Francis; 1994.</Citation></Reference><Reference><Citation>Rosenfeld B, et al. Measuring desire for death among patients with HIV/AIDS: The schedule of attitudes toward hastened death. Am. J. Psychiatry. 1999;156:94&#x2013;100. doi: 10.1176/ajp.156.1.94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/ajp.156.1.94</ArticleId><ArticleId IdType="pubmed">9892303</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahorsu DK, et al. The Fear of COVID-19 Scale: Development and Initial Validation. Int. J. Ment. Health Addict. 2022;20:1537&#x2013;1545. doi: 10.1007/s11469-020-00270-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11469-020-00270-8</ArticleId><ArticleId IdType="pmc">PMC7100496</ArticleId><ArticleId IdType="pubmed">32226353</ArticleId></ArticleIdList></Reference><Reference><Citation>Maclean KA, Leoutsakos J-MS, Johnson MW, Griffiths RR. Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin. J. Sci. Study Relig. 2012;51:721&#x2013;737. doi: 10.1111/j.1468-5906.2012.01685.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-5906.2012.01685.x</ArticleId><ArticleId IdType="pmc">PMC3539773</ArticleId><ArticleId IdType="pubmed">23316089</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett FS, Johnson MW, Griffiths RR. Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin. J. Psychopharmacol. 2015;29:1182&#x2013;1190. doi: 10.1177/0269881115609019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269881115609019</ArticleId><ArticleId IdType="pmc">PMC5203697</ArticleId><ArticleId IdType="pubmed">26442957</ArticleId></ArticleIdList></Reference><Reference><Citation>Roseman L, et al. Emotional breakthrough and psychedelics: Validation of the emotional breakthrough inventory. J. Psychopharmacol. 2019;33:1076&#x2013;1087. doi: 10.1177/0269881119855974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269881119855974</ArticleId><ArticleId IdType="pubmed">31294673</ArticleId></ArticleIdList></Reference><Reference><Citation>Roscoe J, Lozy O. Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in clinical trials. Drug Sci. Policy Law. 2022;8:20503245221085222. doi: 10.1177/20503245221085222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20503245221085222</ArticleId></ArticleIdList></Reference><Reference><Citation>McClain CS, Rosenfeld B, Breitbart W. Effect of spiritual well-being on end-of-life despair in terminally-ill cancer patients. Lancet. 2003;361:1603&#x2013;1607. doi: 10.1016/S0140-6736(03)13310-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(03)13310-7</ArticleId><ArticleId IdType="pubmed">12747880</ArticleId></ArticleIdList></Reference><Reference><Citation>Hovmand OR, Poulsen ED, Arnfred S, Storeb&#xf8; OJ. Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review. J. Psychopharmacol. 2023;37:649&#x2013;659. doi: 10.1177/02698811231180276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/02698811231180276</ArticleId><ArticleId IdType="pmc">PMC10350724</ArticleId><ArticleId IdType="pubmed">37403379</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>